Disparate effects of pharmacotherapy on plasma plasminogen activator inhibitor-1 levels in women with the polycystic ovary syndrome

Hormones

Volumn 12, Issue 4, 2013, Pages 559-566

  Koiou, Ekaterini ^a   Tziomalos, Konstantinos ^a   Katsikis, Ilias ^a   Delkos, Dimitrios ^a   Tsourdi, Elena A ^a   Panidis, Dimitrios ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Hyperandrogenemia; Insulin resistance; Metformin; Orlistat; Plasminogen activator inhibitor 1; Polycystic ovary syndrome; Sibutramine; Weight loss

Indexed keywords

FOLLITROPIN; GLUCOSE; HYDROXYPROGESTERONE; INSULIN; METFORMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; SIBUTRAMINE; TESTOSTERONE; TETRAHYDROLIPSTATIN;

ADULT; ARTICLE; BODY MASS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; EXERCISE; FEMALE; FOLLITROPIN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HIP CIRCUMFERENCE; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LOW CALORY DIET; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MORNING DOSAGE; OBESITY; OVARY FOLLICLE; OVARY POLYCYSTIC DISEASE; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; TESTOSTERONE BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

ADOLESCENT; ADULT; ANDROGENS; ANTI-OBESITY AGENTS; COMORBIDITY; CYCLOBUTANES; DIET, REDUCING; DRUG THERAPY; EXERCISE; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LACTONES; METFORMIN; OBESITY; OVERWEIGHT; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYCYSTIC OVARY SYNDROME; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84891510614     PISSN: 11093099     EISSN: None     Source Type: Journal    
DOI: 10.14310/horm.2002.1444     Document Type: Article

References (35)

1. Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R, 2011 Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat rev endocrinol 7: 219-231.
2. Dunaif A, Segal KR, Futterweit W, Dobrjansky A, 1989 Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38: 1165-1174.
3. Morales AJ, Laughlin GA, Butzow T, et al, 1996 Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features. J Clin endocrinol Metab 81: 2854-2864.
4. Cesari M, Pahor M, Incalzi RA, 2010 Plasminogen activator inhibitor-1 (Pai-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions. Cardiovasc Ther 28: e72-e91.
5. Moran LJ, Hutchison SK, Meyer C, Zoungas S, Teede HJ, 2009 A comprehensive assessment of endothelial function in overweight women with and without poly-cystic ovary syndrome. Clin Sci (Lond) 116: 761-770.
6. Orio F, Jr., Palomba S, Cascella T, et al, 2004 Is plasmi-nogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome? Reprod Biomed online 9: 505-510.
7. Tarkun I, Canturk Z, Arslan BC, Turemen E, Tarkun P, 2004 The plasminogen activator system in young and lean women with polycystic ovary syndrome. Endocr J 51: 467-472.
8. Meigs JB, O'donnell CJ, Tofler GH, et al, 2006 He-mostatic markers of endothelial dysfunction and risk of incident type 2 diabetes: the Framingham offspring Study. Diabetes 55: 530-537.
9. Smith A, Patterson C, Yarnell J, et al, 2005 Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke? The Caerphilly Study. Circulation 112: 3080-3087.
10. Wild RA, Carmina E, Diamanti-Kandarakis E, et al, 2010 Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the androgen excess and Polycystic ovary Syndrome (ae-PCoS) Society. J Clin endocrinol Metab 95: 2038-2049.
11. Norman RJ, Dewailly D, Legro RS, Hickey TE, 2007 Polycystic ovary syndrome. Lancet 370: 685-697.
12. Andersen P, Seljeflot I, Abdelnoor M, et al, 1995 Increased insulin sensitivity and fibrinolytic capacity after dietary intervention in obese women with polycystic ovary syndrome. Metabolism 44: 611-616.
13. Rotterdam eSHre/aSrM-Sponsored PCoS consensus workshop group, 2004 Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCoS). Hum reprod 19: 41-47.
14. Koiou E, Tziomalos K, Katsikis I, et al, 2012 Weight loss significantly reduces serum lipocalin-2 levels in overweight and obese women with polycystic ovary syndrome. Gynecol endocrinol 28: 20-24.
15. Koiou E, Tziomalos K, Dinas K, et al, 2011 The effect of weight loss and treatment with metformin on serum vaspin levels in women with polycystic ovary syndrome. Endocr J 58: 237-246.
16. Piouka A, Farmakiotis D, Katsikis I, et al, 2009 Anti-Mullerian hormone levels reflect severity of PCoS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels. Am J Physiol endocrinol Metab 296: e238-e243.
17. Carter GD, Holland SM, Alaghband-Zadeh J, et al, 1983 Investigation of hirsutism: testosterone is not enough. Ann Clin Biochem 20 (Pt 5): 262-263.
18. Matthews DR, Hosker JP, Rudenski AS, et al, 1985 Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419.
19. Katz A, Nambi SS, Mather K, et al, 2000 Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin endocrinol Metab 85: 2402-2410.
20. Palomba S, Orio F, Jr., Falbo A, et al, 2005 Plasminogen activator inhibitor 1 and miscarriage after metformin treatment and laparoscopic ovarian drilling in patients with polycystic ovary syndrome. Fertil Steril 84: 761-765.
21. Tan BK, Adya R, Chen J, et al, 2009 Metformin decreases angiogenesis via NF-kappaB and erk1/2/erk5 pathways by increasing the antiangiogenic thrombospondin-1. Cardiovasc res 83: 566-574.
22. Teede HJ, Meyer C, Hutchison SK, et al, 2010 Endothe-lial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy. Fertil Steril 93: 184-191.
23. Agarwal N, Rice SP, Bolusani H, et al, 2010 Metformin reduces arterial stiffness and improves endothelial function in young women with polycystic ovary syndrome: a randomized, placebo-controlled, crossover trial. J Clin endocrinol Metab 95: 722-730.
24. Glueck CJ, Wang P, Fontaine R, Tracy T, Sieve-Smith L, 1999 Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome. Metabolism 48: 511-519.
25. Orio F, Jr., Palomba S, Cascella T, et al, 2005 Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study. J Clin endocrinol Metab 90: 6072-6076.
26. Carmassi F, De NF, Fioriti R, et al, 2005 Insulin resistance causes impaired vasodilation and hypofibrinolysis in young women with polycystic ovary syndrome. Thromb res 116: 207-214.
27. Manneras-Holm L, Baghaei F, Holm G, et al, 2011 Coagulation and fibrinolytic disturbances in women with polycystic ovary syndrome. J Clin endocrinol Metab 96: 1068-1076.
28. Diamanti-Kandarakis E, Katsikis I, Piperi C, Alexan-draki K, Panidis D, 2007 Effect of long-term orlistat treatment on serum levels of advanced glycation end-products in women with polycystic ovary syndrome. Clin endocrinol (oxf) 66: 103-109.
29. Florakis D, Diamanti-Kandarakis E, Katsikis I, et al, 2008 Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study. Int J obes (Lond) 32: 692-699.
30. Panidis D, Farmakiotis D, Rousso D, et al, 2008 Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels. Fertil Steril 89: 899-906.
31. Lindholm A, Bixo M, Eliasson M, et al, 2010 Tissue plasminogen activator and plasminogen activator inhibitor 1 in obese and lean patients with polycystic ovary syndrome. Gynecol endocrinol 26: 743-748.
32. Glintborg D, Andersen M, 2010 An update on the patho-genesis, inflammation, and metabolism in hirsutism and polycystic ovary syndrome. Gynecol endocrinol 26: 281-296.
33. Stamets K, Taylor DS, Kunselman A, et al, 2004 A randomized trial of the effects of two types of short-term hypocaloric diets on weight loss in women with polycystic ovary syndrome. Fertil Steril 81: 630-637.
34. Rissanen P, Vahtera E, Krusius T, Uusitupa M, Rissanen A, 2001 Weight change and blood coagulability and fibrinolysis in healthy obese women. Int J obes relat Metab Disord 25: 212-218.
35. James WP, Caterson ID, Coutinho W, et al, 2010 Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N engl J Med 363: 905-917.